Yuma Regional Cancer Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schneider, Bryan
BRE12-158, NCT02101385: Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Completed
2
193
US
Genomically Directed Monotherapy, Observation/Standard Therapy
Bryan Schneider, MD, Hoosier Cancer Research Network, Vera Bradley Foundation for Breast Cancer, Walther Cancer Institute, Strategic Research Initiative Grant through IUSCC
Malignant Neoplasm of Breast, Breast Cancer
02/21
09/22
ECOG-ACRIN EAZ171, NCT04001829: Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Active, not recruiting
2
249
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
09/23
03/27
NCT04534283: A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Terminated
2
16
US
Abemaciclib, LY2835219, LY3214996
Anita Turk, Eli Lilly and Company
Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation
08/23
08/23
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
NCT03896815: Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

No Longer Available
N/A
NA
INCB054329
Incyte Corporation
 
 
EDPO, NCT06081517: Evaluating Disparities in Precision Oncology

Recruiting
N/A
10600
US
Social Determinants of Health and toxicity questionnaires
Indiana University
Metastatic Cancer, Advanced Cancer
12/28
12/28
NCT02610426: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting
N/A
162
US
Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Breast Carcinoma
01/00
01/00
NCT02610413: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Recruiting
N/A
354
US
Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Breast Carcinoma
01/00
01/00
NCT02610439: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Recruiting
N/A
575
US
Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Breast Carcinoma, Neuropathy
01/00
01/00
Chandra, Abhinav
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting
3
225
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo, Corticosteroids
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
04/26
12/28
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25
Olmeda, Amy
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting
3
225
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo, Corticosteroids
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
04/26
12/28

Download Options